RxDoctor Payments Data

Karen Allison

Ophthalmology · New York, NYNPI 1588687750

Payments from drug & device makers

$2,157in general payments, 2019–2025

Across 44 payments — averaging $49.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$757
  • Aerie Pharmaceuticals, Inc.$325
  • Alcon$297
  • Bausch & Lomb Americas Inc.$260
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$254
  • Sight Sciences, Inc.$172
  • plus $93 from 2 others

What the payments were for

  • Speaking & faculty fees$382%
  • Food & beverage$2,03494%
  • Education$854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,157 in reported general payments places this provider in the 60th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$116,501
Medicare patients
336
Services billed
1,434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine215$260,771
RocklatanNetarsudil Mesylat/Latanoprost243$130,794
RhopressaNetarsudil Mesylate201$107,689
LumiganBimatoprost134$84,334
SimbrinzaBrinzolamide/Brimonidine Tart190$58,663
Alphagan PBrimonidine Tartrate65$38,381
Cyclosporine90$32,863
Brimonidine Tartrate820$32,388
XiidraLifitegrast23$27,495
VyzultaLatanoprostene Bunod55$26,836
CombiganBrimonidine Tartrate/Timolol56$23,366
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol154$20,446
Travoprost86$15,631
Latanoprost1,672$15,240
Brinzolamide51$14,895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$757$406,850470 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$325$238,483444 claims
AlconSimbrinza$297$58,663190 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$260$54,33178 claims
NovartisTravatan Z$19$7,31913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →